AU2006230974C1 - Benzimidazole formulation - Google Patents

Benzimidazole formulation Download PDF

Info

Publication number: AU2006230974C1
Authority: AU; Australia
Prior art keywords: dry; alkaline; alkaline substance; benzimidazole; formulation
Prior art date: 2005-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2006230974A

Other languages

English (en)

Other versions

AU2006230974A1 (en

AU2006230974B2 (en

Inventor

Poul Bertelsen

Peder Mohr Olsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharma AS

Original Assignee

Nycomed Danmark AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-11

Filing date

2006-07-11

Publication date

2012-02-02

2006-07-11 Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS

2006-10-12 Publication of AU2006230974A1 publication Critical patent/AU2006230974A1/en

2011-09-29 Application granted granted Critical

2011-09-29 Publication of AU2006230974B2 publication Critical patent/AU2006230974B2/en

2012-02-02 Publication of AU2006230974C1 publication Critical patent/AU2006230974C1/en

2013-07-11 Assigned to TAKEDA PHARMA A/S reassignment TAKEDA PHARMA A/S Request to Amend Deed and Register Assignors: NYCOMED DANMARK APS

Status Ceased legal-status Critical Current

2026-07-11 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AU2006230974A 2005-07-11 2006-07-11 Benzimidazole formulation Ceased AU2006230974C1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200501019		2005-07-11
DKPA200501019		2005-07-11
US72785505P	2005-10-19	2005-10-19
US60/727,855		2005-10-19
PCT/DK2006/000409 WO2006105798A2 (fr)	2005-07-11	2006-07-11	Formulation de benzimidazole

Publications (3)

Publication Number	Publication Date
AU2006230974A1 AU2006230974A1 (en)	2006-10-12
AU2006230974B2 AU2006230974B2 (en)	2011-09-29
AU2006230974C1 true AU2006230974C1 (en)	2012-02-02

Family

ID=37492042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2006230974A Ceased AU2006230974C1 (en)	2005-07-11	2006-07-11	Benzimidazole formulation

Country Status (5)

Country	Link
EP (1)	EP1901719A2 (fr)
AU (1)	AU2006230974C1 (fr)
CA (1)	CA2614526A1 (fr)
EA (1)	EA015535B1 (fr)
WO (1)	WO2006105798A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5228359B2 (ja) *	2007-04-12	2013-07-03	ニプロ株式会社	主薬粒子及びその製造方法ならびに口腔内崩壊錠
AU2009224254A1 (en)	2008-03-11	2009-09-17	Takeda Pharmaceutical Company Limited	Orally-disintegrating solid preparation
TR201000948A1 (tr) *	2010-02-09	2011-08-22	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Aripiprazol formülasyonları.
US9945862B2 (en)	2011-06-03	2018-04-17	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103479593B (zh) *	2013-05-10	2014-10-08	青岛双鲸药业有限公司	一种奥美拉唑肠溶片的制备方法
CN103386133A (zh) *	2013-07-09	2013-11-13	重庆莱美药业股份有限公司	一种质子泵抑制剂的口腔速溶制剂及其制备方法
IL302218B2 (en)	2014-08-28	2024-10-01	Eisai R&D Man Co Ltd	Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja)	2015-02-25	2020-11-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体の苦味抑制方法
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN104825414B (zh) *	2015-05-07	2018-11-16	山东新时代药业有限公司	一种稳定的s-泮托拉唑钠肠溶片
EP3311841B1 (fr)	2015-06-16	2021-07-28	PRISM BioLab Co., Ltd.	Agent anticancéreux
CN108135894B (zh)	2015-08-20	2021-02-19	卫材R&D管理有限公司	肿瘤治疗剂
RU2750539C2 (ru)	2017-02-08	2021-06-29	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en)	2017-05-16	2019-11-21	Eisai R&D Management Co., Ltd.	Treatment of hepatocellular carcinoma
CN113318079B (zh) *	2021-05-13	2024-01-09	江西博莱大药厂有限公司	一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法
CN115645373B (zh) *	2022-12-24	2024-01-30	山东理工职业学院	一种奥美拉唑钠片的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639478A (en) *	1986-02-13	1997-06-17	Takeda Chemical Industries, Ltd.	Method to stabilize a pharmaceutical composition and its production
WO1998050019A1 (fr) *	1997-05-09	1998-11-12	Sage Pharmaceuticals, Inc.	Formes posologiques pharmaceutiques orales stables
EP1004305A1 (fr) *	1998-04-20	2000-05-31	Eisai Co., Ltd.	Compositions stabilisees contenant des composes du type benzimidazole
WO2004075881A1 (fr) *	2003-02-28	2004-09-10	Ranbaxy Laboratories Limited	Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2005009410A2 (fr) *	2003-07-17	2005-02-03	Dr. Reddy's Laboratories, Inc.	Compositions pharmaceutiques a revetement gonflant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001296908A1 (en) *	2000-09-29	2002-04-08	Geneva Pharmaceuticals, Inc.	Proton pump inhibitor formulation
AR036354A1 (es) *	2001-08-31	2004-09-01	Takeda Chemical Industries Ltd	Preparacion solida
EP2112920B1 (fr) *	2003-06-26	2018-07-25	Intellipharmaceutics Corp.	Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif

2006
- 2006-07-11 AU AU2006230974A patent/AU2006230974C1/en not_active Ceased
- 2006-07-11 WO PCT/DK2006/000409 patent/WO2006105798A2/fr not_active Ceased
- 2006-07-11 EP EP06753346A patent/EP1901719A2/fr not_active Withdrawn
- 2006-07-11 CA CA002614526A patent/CA2614526A1/fr not_active Abandoned
- 2006-07-11 EA EA200800290A patent/EA015535B1/ru not_active IP Right Cessation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639478A (en) *	1986-02-13	1997-06-17	Takeda Chemical Industries, Ltd.	Method to stabilize a pharmaceutical composition and its production
WO1998050019A1 (fr) *	1997-05-09	1998-11-12	Sage Pharmaceuticals, Inc.	Formes posologiques pharmaceutiques orales stables
EP1004305A1 (fr) *	1998-04-20	2000-05-31	Eisai Co., Ltd.	Compositions stabilisees contenant des composes du type benzimidazole
WO2004075881A1 (fr) *	2003-02-28	2004-09-10	Ranbaxy Laboratories Limited	Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2005009410A2 (fr) *	2003-07-17	2005-02-03	Dr. Reddy's Laboratories, Inc.	Compositions pharmaceutiques a revetement gonflant

Also Published As

Publication number	Publication date
WO2006105798A2 (fr)	2006-10-12
WO2006105798A3 (fr)	2006-12-07
CA2614526A1 (fr)	2006-10-12
AU2006230974A1 (en)	2006-10-12
EA015535B1 (ru)	2011-08-30
EA200800290A1 (ru)	2008-08-29
EP1901719A2 (fr)	2008-03-26
AU2006230974B2 (en)	2011-09-29

Publication	Publication Date	Title
AU2006230974C1 (en)	2012-02-02	Benzimidazole formulation
JP6574417B2 (ja)	2019-09-11	非晶質ダパグリフロジンを含有する製剤
US5948440A (en)	1999-09-07	Modified release matrix formulation of cefaclor and cephalexin
JP2016164170A (ja)	2016-09-08	プロトンポンプ阻害剤を含む制御放出組成物
CN119112820A (zh)	2024-12-13	来那度胺的口服用片剂组合物
US20110064816A1 (en)	2011-03-17	Atorvastatin compositions
WO2011111027A2 (fr)	2011-09-15	Formulation de comprimé oral dispersible à libération retardée
EP2988733B1 (fr)	2019-03-27	Composition pharmaceutique contenant du macitentan cristallin
WO2008027600A2 (fr)	2008-03-06	Compositions d'imatinib
JP7581052B2 (ja)	2024-11-12	レナリドミドの経口用コーティング錠剤組成物
MX2014007331A (es)	2014-09-01	Sistema de multiunidades de granulos de liberacion inmediata.
EP2601936A1 (fr)	2013-06-12	Composition comprimée
AU2019232937B2 (en)	2020-10-15	Ceritinib formulation
US20070020334A1 (en)	2007-01-25	Benzimidazole formulation
WO2010046418A1 (fr)	2010-04-29	Composition pharmaceutique contenant du lévétiracétam
US20100055177A1 (en)	2010-03-04	Modified release composition of levetiracetam and process for the preparation thereof
EP2934494B1 (fr)	2019-06-12	Formulation pharmaceutique de n-[5-[2-(3,5-diméthoxyphényl)éthyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-diméthylpipérazin-1-yl]benzamide
EP1909761B1 (fr)	2017-01-18	Préparation pharmaceutique comprenant du pantoprazole granulaire
Agiba et al.	2020	Modulatory effect of polymer type and concentration on drug release from sustained release matrix tablets of ranolazine: A comparative release kinetic study
Brijesh et al.	2013	Formulation and evaluation of once daily sustained release matrix tablet of verapamil hydrochloride
JP2024003789A (ja)	2024-01-15	時限放出型顆粒およびその用途
WO2025190465A1 (fr)	2025-09-18	Composition pharmaceutique stable contenant du sélexipag et son procédé de préparation
Naiserová et al.	0	perorálních tablet
GB2334212A (en)	1999-08-18	Modified release matrix formulation for cefaclor and cephalexin
KR20180060174A (ko)	2018-06-07	덱스란소프라졸을 포함하는 경구용 정제 조성물, 이를 포함하는 경구용 정제 및 그 제조방법

Legal Events

Date	Code	Title	Description
2011-10-13	DA2	Applications for amendment section 104	Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 SEP 2011.
2012-02-02	DA3	Amendments made section 104	Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 SEP 2011
2012-02-09	FGA	Letters patent sealed or granted (standard patent)
2016-02-04	MK14	Patent ceased section 143(a) (annual fees not paid) or expired